Clinical Trials
2 trialsNCT04074746 2025-09-30
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03192202 2023-07-20
AFM13 in Relapsed/Refractory Cutaneous Lymphomas
Columbia University
Phase 1/2 Completed